L. Canini Et Al. , "Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection," HEPATOLOGY COMMUNICATIONS , vol.1, no.4, pp.288-292, 2017
Canini, L. Et Al. 2017. Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection. HEPATOLOGY COMMUNICATIONS , vol.1, no.4 , 288-292.
Canini, L., Koh, C., Cotler, S. J., Uprichard, S. L., Winters, M. A., Han, M. A. T., ... Kleiner, D. E.(2017). Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection. HEPATOLOGY COMMUNICATIONS , vol.1, no.4, 288-292.
Canini, Laetitia Et Al. "Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection," HEPATOLOGY COMMUNICATIONS , vol.1, no.4, 288-292, 2017
Canini, Laetitia Et Al. "Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection." HEPATOLOGY COMMUNICATIONS , vol.1, no.4, pp.288-292, 2017
Canini, L. Et Al. (2017) . "Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection." HEPATOLOGY COMMUNICATIONS , vol.1, no.4, pp.288-292.
@article{article, author={Laetitia Canini Et Al. }, title={Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection}, journal={HEPATOLOGY COMMUNICATIONS}, year=2017, pages={288-292} }